Company Description
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China.
The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.
It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China.
China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.
| Country | China |
| Founded | 2005 |
| IPO Date | Jan 4, 2019 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 78 |
| CEO | Feng Zhou |
Contact Details
Address: 178 Taidong Road North Taizhou, F4 225300 China | |
| Phone | 8652386298290 |
| Website | sxtchina.com |
Stock Details
| Ticker Symbol | SXTC |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001723980 |
| CUSIP Number | G2161P108 |
| ISIN Number | VGG2161P1403 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Feng Zhou | Chairman of the Board and Chief Executive Officer |
| Xiaodong Pan | Chief Financial Officer |
| Jun Zheng | Executive Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 5, 2024 | 6-K | Report of foreign issuer |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 11, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jul 31, 2023 | 20-F | Annual and transition report of foreign private issuers |
| May 19, 2023 | 20-F/A | Filing |
| Mar 29, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 29, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 27, 2023 | 424B7 | Filing |
| Mar 23, 2023 | 6-K | Report of foreign issuer |